97 results
8-K
EX-99.1
ACST
Acasti Pharma Inc.
9 Aug 24
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
8:00am
value of our derivative warrant liabilities, offset in part by a $1.6 million increase in research and development expenses.
Total research
424B3
ACST
Acasti Pharma Inc.
7 Aug 24
Prospectus supplement
4:14pm
by an applicable income tax treaty) on the gain derived from such sale or other disposition, which may be offset by certain U.S. source capital losses, if any. We … swaps, collars or units of exchange funds that are designed to hedge or offset a decrease in market value of equity securities granted as compensation
8-K
EX-99.1
s93ve60mzbr k8lxxm7i
21 Jun 24
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
8:00am
8-K
EX-99.1
f0mh3lmd7k3
12 Feb 24
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
8:00am
8-K
EX-99.1
iospnx
13 Nov 23
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
12:00am
8-K
EX-99.1
bd2tuvn
14 Nov 22
Acasti Pharma Reports Second Quarter 2023 Operational Results
7:15am
8-K
EX-99.1
pexiqm bp6
11 Aug 22
Acasti Pharma Reports First Quarter 2023 Operational Results
7:05am